Healthcare provider profile · identity verified

Daniel J Fields, M.D.

Family Practice · PLYMOUTH, CA · NPI 1801907308

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	869	271
Levothyroxine Sodium	Levothyroxine Sodium	401	100
Amlodipine Besylate	Amlodipine Besylate	361	106
Lisinopril	Lisinopril	301	86
Metformin Hcl Er	Metformin Hcl	267	86
Gabapentin	Gabapentin	225	70
Metoprolol Succinate	Metoprolol Succinate	221	73
Albuterol Sulfate Hfa	Albuterol Sulfate	219	85
Rosuvastatin Calcium	Rosuvastatin Calcium	212	54
Losartan Potassium	Losartan Potassium	205	59
Omeprazole	Omeprazole	185	61
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	174	49
Zolpidem Tartrate	Zolpidem Tartrate	168	40
Hydrochlorothiazide	Hydrochlorothiazide	161	48
Trazodone Hcl	Trazodone Hcl	161	45
Tamsulosin Hcl	Tamsulosin Hcl	149	47
Duloxetine Hcl	Duloxetine Hcl	126	32
Eliquis	Apixaban	124	31
Furosemide	Furosemide	109	31
Allopurinol	Allopurinol	102	33
Fluoxetine Hcl	Fluoxetine Hcl	98	33
Fluticasone Propionate	Fluticasone Propionate	98	40
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	98	30
Potassium Chloride	Potassium Chloride	97	31
Sertraline Hcl	Sertraline Hcl	91	23
Tramadol Hcl	Tramadol Hcl	91	32
Trulicity	Dulaglutide	89	15
Baclofen	Baclofen	88	28
Famotidine	Famotidine	87	21
Bupropion Xl	Bupropion Hcl	85	26
Glipizide Er	Glipizide	84	27
Jardiance	Empagliflozin	78	22
Alendronate Sodium	Alendronate Sodium	77	29
Olmesartan Medoxomil	Olmesartan Medoxomil	77	26
Pantoprazole Sodium	Pantoprazole Sodium	75	25
Simvastatin	Simvastatin	71	19
Finasteride	Finasteride	70	16
Ibuprofen	Ibuprofen	69	18
Ozempic	Semaglutide	68	23
Metformin Hcl	Metformin Hcl	66	19
Warfarin Sodium	Warfarin Sodium	65	18
Carvedilol	Carvedilol	63	18
Ezetimibe	Ezetimibe	62	suppressed
Meloxicam	Meloxicam	61	23
Metoprolol Tartrate	Metoprolol Tartrate	61	23
Buspirone Hcl	Buspirone Hcl	58	14
Citalopram Hbr	Citalopram Hydrobromide	58	13
Amitriptyline Hcl	Amitriptyline Hcl	53	14
Farxiga	Dapagliflozin Propanediol	53	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	51	12
Quetiapine Fumarate	Quetiapine Fumarate	47	13
Escitalopram Oxalate	Escitalopram Oxalate	44	14
Oxycodone Hcl	Oxycodone Hcl	42	suppressed
Propranolol Hcl	Propranolol Hcl	42	13
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	41	suppressed
Topiramate	Topiramate	40	13
Synthroid	Levothyroxine Sodium	39	12
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	38	suppressed
Januvia	Sitagliptin Phosphate	38	11
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	37	suppressed
Spironolactone	Spironolactone	37	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	37	suppressed
Breo Ellipta	Fluticasone/Vilanterol	36	suppressed
Pregabalin	Pregabalin	35	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	34	17
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	34	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	32	17
Montelukast Sodium	Montelukast Sodium	32	12
Olanzapine	Olanzapine	32	suppressed
Arnuity Ellipta	Fluticasone Furoate	31	suppressed
Benazepril Hcl	Benazepril Hcl	31	suppressed
Ondansetron Odt	Ondansetron	30	suppressed
Clopidogrel	Clopidogrel Bisulfate	29	11
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	29	suppressed
Paroxetine Hcl	Paroxetine Hcl	29	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	28	suppressed
Bupropion Hcl Sr	Bupropion Hcl	27	suppressed
Celecoxib	Celecoxib	27	11
Primidone	Primidone	27	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	26	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	26	suppressed
Terazosin Hcl	Terazosin Hcl	26	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	25	suppressed
Irbesartan	Irbesartan	23	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	23	21
Testosterone Cypionate	Testosterone Cypionate	23	suppressed
Buprenorphine-Naloxone	Buprenorphine Hcl/Naloxone Hcl	22	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	22	suppressed
Ventolin Hfa	Albuterol Sulfate	22	suppressed
Cephalexin	Cephalexin	21	17
Lorazepam	Lorazepam	21	11
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	21	suppressed
Ropinirole Hcl	Ropinirole Hcl	21	suppressed
Amoxicillin	Amoxicillin	20	suppressed
Aripiprazole	Aripiprazole	20	suppressed
Glipizide	Glipizide	19	suppressed
Pravastatin Sodium	Pravastatin Sodium	19	suppressed
Solifenacin Succinate	Solifenacin Succinate	19	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	19	suppressed
Prednisone	Prednisone	18	11
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	17	suppressed
Varenicline Tartrate	Varenicline Tartrate	17	suppressed
Acyclovir	Acyclovir	16	suppressed
Amlodipine-Valsartan	Amlodipine Besylate/Valsartan	16	suppressed
Combivent Respimat	Ipratropium/Albuterol Sulfate	16	suppressed
Estradiol	Estradiol	16	suppressed
Fluorouracil	Fluorouracil	16	13
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	15	suppressed
Buprenorphine Hcl	Buprenorphine Hcl	15	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	15	suppressed
Xarelto	Rivaroxaban	15	suppressed
Azelastine Hcl	Azelastine Hcl	14	suppressed
Enalapril Maleate	Enalapril Maleate	14	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	14	suppressed
Klor-Con 10	Potassium Chloride	14	suppressed
Lovastatin	Lovastatin	14	suppressed
Naproxen	Naproxen	14	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	14	14
Temazepam	Temazepam	14	suppressed
Testosterone	Testosterone	14	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	14	suppressed
Atomoxetine Hcl	Atomoxetine Hcl	13	suppressed
Butalb-Acetaminoph-Caff-Codein	Butalbit/Acetamin/Caff/Codeine	13	suppressed
Carbamazepine	Carbamazepine	13	suppressed
Fluocinonide	Fluocinonide	13	suppressed
Imipramine Hcl	Imipramine Hcl	13	suppressed
Midodrine Hcl	Midodrine Hcl	13	suppressed
Nifedipine Er	Nifedipine	13	suppressed
Phenytoin Sodium Extended	Phenytoin Sodium Extended	13	suppressed
Valacyclovir	Valacyclovir Hcl	13	suppressed
Ketoconazole	Ketoconazole	12	suppressed
Lamotrigine	Lamotrigine	12	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	12	suppressed
Loperamide	Loperamide Hcl	12	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	12	suppressed
Clonazepam	Clonazepam	11	suppressed
Mirtazapine	Mirtazapine	11	suppressed
Nitroglycerin	Nitroglycerin	11	11

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error